Full-Time

High Throughput Assay Senior Research Scientist

Screening & Data Analysis

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$117k - $175.5k/yr

+ Annual Bonus + Equity Awards

Senior

Company Does Not Provide H1B Sponsorship

San Diego, CA, USA

This is an onsite position requiring five days per week in the office.

Category
Data Science
Data Analysis
Data & Analytics
Required Skills
Python
Data Science
R
Machine Learning
MATLAB
Data Analysis
Requirements
  • Ph.D. in Biology, Chemistry, Biochemistry, Computational Biology, Data Science, or a related field with 2-5+ years of relevant industry experience; or a Master’s degree with 5+ years of experience
  • Expertise in assay development, high-throughput screening, and small molecule profiling
  • Proficiency in analyzing large-scale data sets using tools such as GeneData, Spotfire, or similar platforms
  • Advanced coding skills in programming languages such as Python, R, or MATLAB to access, manipulate, and analyze data tables
  • Demonstrated experience applying machine learning and AI methodologies to solve complex research problems
  • Proven ability to work in cross-disciplinary teams and manage multiple projects simultaneously
  • Strong analytical and problem-solving skills
  • Excellent communication and collaboration abilities
  • Innovative mindset with a focus on continuous learning and improvement
  • Attention to detail and commitment to high-quality work
Responsibilities
  • Design, develop, and validate cell-based assays to support high-throughput screening (HTS) and small molecule profiling
  • Lead the execution of HTS campaigns, ensuring high data quality, reproducibility, and traceability
  • Analyze and interpret large-scale data sets using advanced analytical tools and methodologies
  • Utilize software platforms such as GeneData and other common screening analysis tools to manage and analyze screening data
  • Develop custom scripts and pipelines to access, manipulate, and analyze data tables for advanced analytics
  • Apply machine learning (ML) and artificial intelligence (AI) techniques to extract insights, optimize processes, and drive innovation in assay development and profiling
  • Collaborate with cross-functional teams, including computational biologists, chemists, and data scientists, to design experiments and interpret results
  • Stay current with emerging technologies and trends in HTS, data analytics, ML, and AI, integrating them into ongoing projects
  • Contribute to a collaborative, knowledge-sharing team culture
  • Prepare technical reports, presentations, and publications to document and communicate findings internally and externally
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's partnership with Orna could lead to breakthroughs in gene therapy solutions.
  • Recent investments indicate strong investor confidence in Vertex's strategic direction.
  • Vertex's reaffirmed stock rating suggests stability and potential for steady growth.

What critics are saying

  • Increased competition in cystic fibrosis treatments could impact Vertex's market share.
  • High costs of gene-editing therapies may limit their commercial success.
  • Regulatory challenges could delay approvals for Vertex's new gene-editing therapies.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • Partnerships with Arbor and Orna enhance Vertex's gene-editing and cell therapy capabilities.
  • Vertex's innovative R&D approach sets it apart in the biotechnology industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.

Stat News
Mar 18th, 2025
Genetics expert is first NIH director to leave under Trump

He will be replaced on an interim basis by Director Ian Smith, a former Vertex Pharmaceuticals executive.

GlobeNewswire
Mar 18th, 2025
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into...

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).